Metformin × cardiovascular events

TrialLancet (London, England)2024

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

Amanda I Adler et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 5,102 people · 2024

Randomised comparison

Reduced cardiovascular events

−20.0percentage points−32.0 to −5.00

As reported

difference −20.0 %, 95% CI −32.0 to −5.00

Not counted

Reduced cardiovascular events

−10.0percentage points−17.0 to −2.00

As reported

difference −10.0 %, 95% CI −17.0 to −2.00

Two numbers in the abstract

the abstract, start to end

overall relative risk reductions of 20% (95% CI 5-32; p=0.010) for

overall relative risk reductions of 10% (95% CI 2-17; p=0.015) for

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
−20.0−32.0 to −5.00
Cardiovascular events
−10.0−17.0 to −2.00
MetforminSulfonylureas & glinidesInsulinCardiovascular events

Metformin × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

84 papers cite itlatest 60 shown

2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 38772405